How TRIPS Patent Rules Shape Global Access to Generic Medicines

When you take a generic version of a blood pressure or HIV drug, you might think it's just cheaper medicine. But behind that pill is a decades-long battle over patent policy, international trade rules, and who gets to live - and who gets left behind. The TRIPS Agreement is a global legal framework under the World Trade Organization that sets minimum standards for patent protection, including for pharmaceuticals. It came into force in 1995 and changed everything about how generic drugs are made, sold, and distributed around the world.

What TRIPS Actually Does to Generic Drugs

Before TRIPS, many developing countries didn’t even allow patents on drugs. They could make their own versions using different manufacturing methods - called process patents - and sell them cheaply. India, for example, was a global hub for generic HIV and cancer drugs because it only protected the process, not the final product. That meant a drug costing $10,000 a year in the U.S. could be made in India for $200. But TRIPS changed that. It forced every WTO member - 164 countries - to grant product patents on medicines for at least 20 years from the filing date. No more shortcuts. No more workarounds. If a drug is patented, you can’t make it, even if you use a different method.

That 20-year rule sounds fair - until you realize it starts counting from when the patent is filed, not when the drug hits the market. Many drugs sit in regulatory review for years before approval. So by the time a generic version can legally enter the market, the effective monopoly might already be 25 years long. Add in data exclusivity - where regulators can’t use the original company’s clinical trial data to approve generics - and you’re looking at 5 to 10 more years of no competition. That’s why, in places like South Africa and Brazil, prices for new HIV drugs didn’t drop for over a decade after TRIPS kicked in.

The Compulsory License Loophole (That Almost Doesn’t Work)

TRIPS does have a built-in escape hatch: compulsory licensing. Article 31 says a government can force a patent holder to let someone else make the drug - without permission - if there’s a public health emergency. Sounds great, right? But here’s the catch: the license can only be used to supply the domestic market. So if Nigeria needs 10 million doses of a cancer drug but can’t produce it, it can’t import cheaper versions from India. India can’t export under its own compulsory license because TRIPS says it has to be for its own people.

This rule was a disaster for countries without drug factories. In 2001, the Doha Declaration tried to fix it by affirming that public health trumps patents. But it didn’t change the law - just said countries could interpret it more flexibly. The real fix came in 2005: the "Paragraph 6 Solution," which allowed countries to export generics made under compulsory license. Sounds like progress? Not really. Only two countries ever used it: Canada and Rwanda. Canada made a small shipment of HIV drugs to Rwanda in 2007. That was it. The paperwork was too complex. The legal risks too high. The pharmaceutical industry too loud. By 2016, only one shipment of malaria medicine had been sent under this rule.

TRIPS Plus: The Hidden Rules That Hurt More

Even if a country follows TRIPS exactly, it’s still getting squeezed. That’s because rich countries don’t stop at TRIPS. They push "TRIPS Plus" rules into bilateral trade deals. The U.S., EU, and Switzerland routinely demand extra protections in exchange for market access. These include:

• Extending patent terms beyond 20 years
• Imposing data exclusivity periods longer than TRIPS allows
• Banning parallel imports (buying cheaper versions from other countries)
• Requiring patent linkage - where drug regulators must check patent status before approving generics

By 2020, 85% of U.S. free trade agreements included these stricter rules. The EU-Vietnam deal, signed in 2020, gave eight years of data exclusivity - four years longer than TRIPS permits. Countries like Thailand and Brazil tried to use compulsory licenses for HIV drugs. They were hit with threats of trade sanctions. The message was clear: follow our rules, or face consequences.

Who Pays the Price?

The numbers don’t lie. In 1995, only 60 developing countries had product patents on medicines. By 2010, that number jumped to 147. The result? Prices for patented drugs soared. A 2001 study in the Journal of the American Medical Association found average price increases of over 200% in developing countries. In India, after switching to product patents in 2005, the cost of some cancer drugs jumped 300-500%. The World Health Organization found that 70% of new drugs approved between 1975 and 1997 were for diseases affecting rich countries - and only 13 were for tropical diseases like malaria or sleeping sickness. The market didn’t just ignore these diseases; it actively punished countries that tried to fix them.

Meanwhile, generic manufacturers in India, Brazil, and South Africa - once the backbone of global access - now face legal threats, patent lawsuits, and export bans. In 2001, 40 pharmaceutical companies sued South Africa over its law allowing generic imports. The case was dropped only after global protests. Brazil produced generic antiretrovirals in 2000 and got threatened with U.S. trade sanctions under Section 301. It worked - the U.S. backed down, but the message was sent: don’t challenge patents.

What Changed After COVID-19?

The pandemic forced the world to look at TRIPS again. In October 2020, India and South Africa proposed a temporary waiver of TRIPS protections for COVID-19 vaccines, tests, and treatments. Over 100 countries supported it. The U.S., EU, and Switzerland opposed it. The fight lasted over a year. In June 2022, the WTO agreed to a partial waiver - but only for vaccines, not treatments or diagnostics. And even that waiver has strings: countries must notify the WTO, and the waiver expires in 2025. It’s a symbolic win, but not a structural fix. The same system that blocked access to HIV drugs in the 2000s is still in place today.

The Real Winners and Losers

On one side, pharmaceutical companies argue that strong patents drive innovation. They point out that 73% of new medicines since 2000 came from companies in countries with strong IP protection. That’s true - but it’s also true that 80% of those drugs are for conditions affecting wealthy populations. The same companies that lobby for patent extensions in Africa are not investing in drugs for neglected diseases. The Medicines Patent Pool, a nonprofit that negotiates voluntary licenses with drugmakers, has helped 17.4 million people get HIV, hepatitis C, and TB treatments since 2010. But it only works because companies choose to license - not because they’re forced to.

On the other side, countries with weak manufacturing capacity - like most of sub-Saharan Africa - are stuck. They can’t make generics. They can’t import them legally. And they can’t afford the branded versions. The Global Fund reports that while first-line HIV treatment dropped from $10,000 per patient per year in 2000 to $75 in 2019, second-line drugs still cost $300-$600. That’s because second-line drugs are newer, patented, and protected by data exclusivity. No generics yet. No competition. No price drop.

Is There a Way Forward?

There are solutions - but they require political will, not just legal tweaks. Countries need to:

• Use TRIPS flexibilities aggressively - compulsory licensing, parallel imports, and exceptions for public health
• Build regional manufacturing hubs - like the African Medicines Agency - to reduce dependence on imports
• Reject TRIPS Plus in trade deals - no more data exclusivity, no more patent term extensions
• Push for a full TRIPS waiver on essential medicines - not just during pandemics, but permanently

India and South Africa proved it’s possible: they produced life-saving drugs at scale. But they were punished for it. The system isn’t broken - it was designed this way. To protect profits. To delay competition. To keep prices high. Until that changes, millions will keep dying not because medicine doesn’t exist - but because the rules say they can’t have it.